TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06234423: A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Sponsor: OnCusp Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 263 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$8,984,976

Rescue Site Savings

+$5,937,624

Unlock Full NCT06234423 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06234423 Rescue Dossier →